This number is generally lower than seen in routine clinical practice over 12 months and is likely to be related to a reduction in face-face appointments and limited band adjustments during the Covid-19 pandemic
Key Players in the Obesity GLP-1 Market Novo Nordisk Eli Lilly and Company Amgen BoehringerIngelheim AstraZeneca Pfizer Roche Viking Therapeutics Structure Therapeutics Zealand Pharma Scope of the Report Obesity GLP-1 Market by Segments By Molecule Class: Semaglutide Tirzepatide Other GLP-1 Receptor Agonists By Route of Administration: Injectables Oral Formulations By Payer Type: Public Coverage Private Insurance and Self-Pay By Use-Case Framing: Weight Management Cardiovascular Risk Anchored By Region: North America United States Canada Mexico Europe Germany United Kingdom France Italy Spain Netherlands Rest of Europe East Asia China Japan South Korea South Asia and Pacific India Australia New Zealand Frequently Asked Questions How big is the obesity GLP-1 market in 2025

As of 2022, GLP-1RAs have been recommended as first-line treatments, along with SGLT-2 inhibitors, for patients with T2DM and cardiovascular disease in American Diabetes Associations Standards of Medical Care in Diabetes (248, 249)
At that concentration, each 0.1 mL (10 units on a standard U-100 insulin syringe) contains 250 mcg of retatrutide
The extended-release formulation improves adherence and reduces the peak-related gastrointestinal side effects seen with twice-daily exenatide
But surgery isnt your only option